15,270
Total Claims
$1.6M
Drug Cost
905
Beneficiaries
$1,796
Cost/Patient
Peer Comparison vs. 106,889 Family Practice providers
+68%
Cost per patient vs peers
$1,796 vs $1,068 avg
+18%
Brand preference vs peers
10.6% vs 9.0% avg
Brand vs Generic
89% generic
Brand: 1,607 claims · $1.3M
Generic: 13,493 claims · $349K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dulaglutide | 209 | $268K |
| Empagliflozin | 167 | $212K |
| Semaglutide | 43 | $110K |
| Sitagliptin Phosphate | 71 | $106K |
| Semaglutide | 73 | $83K |
| Rivaroxaban | 54 | $81K |
| Apixaban | 45 | $53K |
| Insulin Glargine,hum.Rec.Anlog | 56 | $48K |
| Insulin Detemir | 36 | $34K |
| Tirzepatide | 26 | $33K |
| Dapagliflozin Propanediol | 22 | $32K |
| Olmesartan/Hydrochlorothiazide | 394 | $25K |
| Rosuvastatin Calcium | 853 | $23K |
| Insulin Glargine,hum.Rec.Anlog | 32 | $21K |
| Glipizide | 416 | $19K |
Prescribing Profile
Patient Profile
73
Avg Age
52%
Female
1.42
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data